2026-09-20T12:12:51Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1180212022-01-13T07:54:05Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Alexander Slocum.
Leibowitz, Dalia
Massachusetts Institute of Technology. Department of Mechanical Engineering.
Massachusetts Institute of Technology. Department of Mechanical Engineering
2018-09-17T15:54:08Z
2018-09-17T15:54:08Z
2018
2018
http://hdl.handle.net/1721.1/118021
1051458437
Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2018.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 97-100).
Tuberculosis (TB) affects millions of people all over the world, and in India has an incidence figure of about 2.8 million individuals annually. The TB treatment regime is quite involved, generally requiring six months and multiple medications. A lack of medication adherence can lead to drug-resistant TB. One current method to improve adherence requires the medicine to be dispensed multiple times a week at directly observed treatment (DOT) clinics, a practice which is neither convenient for patients nor completely effective for purposes of adherence. A suite of technologies is being developed to introduce a large-dose drug delivery device into the gastrointestinal (GI) tract. This device would release a discrete amount of drugs every day over the course of a month. The device would be deployed into the stomach through a short-term nasogastric tube placement, and the device would be removed and replaced with a new device after one month. The medication required for a month of treatment can be transferred into a drug delivery device in the stomach via a standard nasogastric tube. Testing conducted on this medication transportation process has showed that 1 month's worth of medication can be placed into a device in the stomach in 7 minutes. In addition to device design, a series of questionnaires are being implemented to ask TB doctors and patients about the feasibility and acceptability of short-term nasogastric tube usage for TB treatment. This device and treatment method has the potential to assist in eradicating TB and allow millions more convenient and effective TB treatment.
by Dalia Leibowitz.
S.M.
100 pages
eng
Massachusetts Institute of Technology
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
http://dspace.mit.edu/handle/1721.1/7582
Mechanical Engineering.
Design of a large-dose minimally invasive drug delivery device for Tuberculosis
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="daba9fc4-54bb-4d8c-8bab-a016bb9783d3">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Design of a large-dose minimally invasive drug delivery device for Tuberculosis</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2018</PublicationDate>
<Authors>
<Author>
<DisplayName>Leibowitz, Dalia</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Mechanical Engineering.</Keyword>
<Abstract>Tuberculosis (TB) affects millions of people all over the world, and in India has an incidence figure of about 2.8 million individuals annually. The TB treatment regime is quite involved, generally requiring six months and multiple medications. A lack of medication adherence can lead to drug-resistant TB. One current method to improve adherence requires the medicine to be dispensed multiple times a week at directly observed treatment (DOT) clinics, a practice which is neither convenient for patients nor completely effective for purposes of adherence. A suite of technologies is being developed to introduce a large-dose drug delivery device into the gastrointestinal (GI) tract. This device would release a discrete amount of drugs every day over the course of a month. The device would be deployed into the stomach through a short-term nasogastric tube placement, and the device would be removed and replaced with a new device after one month. The medication required for a month of treatment can be transferred into a drug delivery device in the stomach via a standard nasogastric tube. Testing conducted on this medication transportation process has showed that 1 month's worth of medication can be placed into a device in the stomach in 7 minutes. In addition to device design, a series of questionnaires are being implemented to ask TB doctors and patients about the feasibility and acceptability of short-term nasogastric tube usage for TB treatment. This device and treatment method has the potential to assist in eradicating TB and allow millions more convenient and effective TB treatment.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>